Legal & General Group Plc Takes Position in Viridian Therapeutics, Inc. $VRDN

Legal & General Group Plc acquired a new stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 64,788 shares of the company's stock, valued at approximately $1,190,000. Legal & General Group Plc owned about 0.06% of Viridian Therapeutics at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. MetLife Investment Management LLC boosted its stake in Viridian Therapeutics by 0.8% during the 4th quarter. MetLife Investment Management LLC now owns 43,985 shares of the company's stock worth $1,369,000 after acquiring an additional 356 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Viridian Therapeutics by 0.3% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 139,360 shares of the company's stock valued at $4,337,000 after purchasing an additional 380 shares in the last quarter. US Bancorp DE increased its stake in Viridian Therapeutics by 23.2% in the third quarter. US Bancorp DE now owns 2,457 shares of the company's stock valued at $53,000 after purchasing an additional 463 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in Viridian Therapeutics by 0.3% in the first quarter. Bank of New York Mellon Corp now owns 216,525 shares of the company's stock worth $4,235,000 after purchasing an additional 659 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Viridian Therapeutics by 1.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,276 shares of the company's stock worth $669,000 after purchasing an additional 876 shares during the period.

Insider Buying and Selling at Viridian Therapeutics

In related news, insider Jennifer Tousignant sold 14,212 shares of the stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $24.50, for a total transaction of $348,194.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.40% of the stock is owned by corporate insiders.

Viridian Therapeutics Price Performance

Shares of NASDAQ VRDN opened at $22.92 on Tuesday. The firm has a market cap of $2.60 billion, a PE ratio of -6.80 and a beta of 0.97. The company has a current ratio of 16.95, a quick ratio of 16.95 and a debt-to-equity ratio of 0.43. Viridian Therapeutics, Inc. has a 1-year low of $13.18 and a 1-year high of $34.29. The company has a fifty day moving average price of $21.19 and a 200 day moving average price of $20.44.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.03) by ($0.02). Viridian Therapeutics had a negative return on equity of 72.97% and a negative net margin of 505.86%.The firm had revenue of $0.28 million for the quarter, compared to the consensus estimate of $0.06 million. Research analysts predict that Viridian Therapeutics, Inc. will post -4.07 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

VRDN has been the subject of several research analyst reports. Needham & Company LLC reissued a "buy" rating and issued a $32.00 price target on shares of Viridian Therapeutics in a report on Monday, June 29th. Royal Bank Of Canada raised their price objective on Viridian Therapeutics from $35.00 to $36.00 and gave the stock an "outperform" rating in a research note on Friday, August 7th. Truist Financial lifted their target price on Viridian Therapeutics from $38.00 to $39.00 and gave the stock a "buy" rating in a report on Friday, August 7th. Wall Street Zen cut Viridian Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday, August 1st. Finally, Evercore set a $26.00 price target on Viridian Therapeutics in a report on Friday, May 15th. Twelve investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $38.54.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc NASDAQ: VRDN is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company's lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.